Sensei Biotherapeutics dosed the first patient in a Phase 1b/2 trial of PIKTOR (sapanisertib + serabelisib) in HR+/HER2- advanced breast cancer. The multi-node PI3K/AKT/mTOR inhibitor previously showed a 47% overall response rate in a Phase 1b trial.
Recent studies demonstrate that blood-based biomarkers combined with AI can predict dementia risk 25 years early in women, identify liver cancer-prone environments with 93% accuracy, and classify prediabetes risk groups with 90% accuracy.
Can-Fite BioPharma's drug candidate namodenoson met its primary endpoint in a Phase 2a pancreatic cancer trial and demonstrated anti-obesity effects in a peer-reviewed preclinical study published in the International Journal of Obesity.
Researchers at RIKEN Center for Integrative Medical Sciences in Japan have developed a machine-learning algorithm that predicts hepatocellular carcinoma risk by analyzing the MYCN protein and tumor-promoting microenvironments in liver tissue before malignancy manifests.
Researchers develop machine-learned biomarker predicting liver cancer risk with 93% accuracy, while AI-driven drug repurposing offers faster, cost-effective alternatives to address cancer survivorship gaps.
